camizestrant
Small moleculeexperimental
Clinical trial activity
18 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
9
Phase 3
5
Phase 4
0
Earliest trial started Oct 11, 2018 (NCT03616587)
Timeline
Indications
Mechanism of action
- Estrogen receptor alphaDEGRADER
Estrogen receptor alpha degrader
Antagonises, leads to degradation
- Estrogen receptor alphaMODULATOR
ESR1 modulator
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@H](c2ccc(NC3CN(CCCF)C3)cn2)N1CC(F)(F)F- Mol. weight
- 476.52 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650365 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07195227 | Phase 2 | Dec 1, 2025 | MedSIR |
| NCT06547164 | Phase 1 | Aug 27, 2024 | AstraZeneca |
| NCT06380751 | Phase 3 | Aug 1, 2024 | AstraZeneca |
| NCT06188520 | Phase 1/Phase 2 (Phase 2) | Dec 5, 2023 | AstraZeneca, University of Cambridge |
| NCT05952557 | Phase 3 | Oct 5, 2023 | AstraZeneca |
| NCT05774951 | Phase 3 | Mar 31, 2023 | AstraZeneca |
| NCT05790304 | Phase 1 | Feb 20, 2023 | AstraZeneca |
| NCT05551897 | Phase 1 | Oct 4, 2022 | AstraZeneca, Parexel |
| NCT05438303 | Phase 1 | Jun 13, 2022 | AstraZeneca |
| NCT05364255 | Phase 1 | May 10, 2022 | AstraZeneca, Quotient |
| NCT04818632 | Phase 1 | Oct 11, 2021 | AstraZeneca, Fudan University |
| NCT04964934 | Phase 3 | Jun 30, 2021 | AstraZeneca |
| NCT04711252 | Phase 3 | Jan 28, 2021 | AstraZeneca |
| NCT04588298 | Phase 2 | Nov 2, 2020 | AstraZeneca, University of Nottingham |
| NCT04541433 | Phase 1 | Sep 29, 2020 | AstraZeneca |
| NCT04546347 | Phase 1 | Sep 17, 2020 | AstraZeneca, Quotient |
| NCT04214288 | Phase 2 | Jan 15, 2020 | AstraZeneca |
| NCT03616587 | Phase 1 | Oct 11, 2018 | AstraZeneca, University of Cambridge |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 17 | 17 | 3 | 2018 |
| Quotient | For profit | 2 | 0 | 1 | 2020 |
| University of Cambridge | Academic/Hospital | 2 | 0 | 2 | 2018 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| MedSIR | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Parexel | For profit | 1 | 0 | 1 | 2022 |
| University of Nottingham | Academic/Hospital | 1 | 0 | 1 | 2020 |
7 organizations
Page 1 / 1